Sun Pharma to settle with some litigants in antitrust case
Sun Pharma and its arm have entered into settlements with certain complainants in an antitrust case currently pending in the US07-07-2017
07-07-2017
Updates
Sub: Intimation of settlement in re Modafinil Antitrust Litigation matter in US Please note that Sun Pharmaceutical Industries Ltd., and one of its wholly-owned subsidiaries have entered into settlements with certain plaintiffs in re Modafinil Antitrust Litigation matter currently pending in the United States District Court for the Eastern District of Pennsylvania. The settlements extend to all claims brought by Apotex Corporation and...07-07-2017
Sun Pharma gains on signing deal a new deal
Following the development, the stock gained 0.88 per cent to Rs 556.75 on BSE.05-07-2017
Sun Pharma inks $55.5 mn deal with Samsung BioLogics
Sun Pharma and Samsung BioLogics have announced a long-term manufacturing agreement for Tildrakizumab used for the treatment of psoriasis. The agreement was entered into by Sun Pharma's...04-07-2017
Press Release
Dear Sirs, Sub: Press Release We are pleased to enclose herewith our Press Release relating to strategic manufacturing tie-up with Samsung BioLogics for Tildrakizumab, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,04-07-2017
Sun Pharma to develop chikungunya, zika drugs
Sun Pharmaceutical Industries has tied up with Pune-based National Institute of Virology to develop new drugs to treat chickungunya, dengue and zika. The partnership is a part of company's plans to develop drugs which cater to unmet needs of patients. Currently there are no vaccines or specific drugs to treat them and thus pose a health concern globally.Under the agreement NIV will conduct the tests on biological, chemical and phytopharmaceutical (plant based) molecules developed by the company against the viruses." We will work with NIV on pre-clinical studies and based on the results we will conduct clinical trials," said Dr Altaf Lal, senior adviser (global health and innovation), Sun Pharma.Sun Pharma did not disclose project funding and commercial development details.The tie up is also in sync with government's Make in India plan, the company said. Sun Pharma's agreement with NIV follows its MoU with Indian Council for Medical Research for conducting joint scientific research...27-06-2017
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India27-06-2017
Press Release
We are pleased to enclose herewith our Press Release relating to agreement between Sun Pharma & NIV to fight Zika, Chikungunya and Dengue, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,27-06-2017
Disclosure of Voting results of Court Convened Meeting (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Sun Pharmaceutical Industries Ltd has informed BSE regarding the details of Voting results of Court Convened Meeting, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here22-06-2017
Voting Results Of National Company Law Tribunal ('NCLT") Convened Meeting Of The Equity Shareholders Of The Company Held On June 20, 2017 Along With Scrutinizers' Report
Pursuant to the requirements of Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, we enclose herewith the details of the result of remote e-voting, postal ballot and poll conducted at the NCLT convened meeting of equity shareholders of Sun Pharmaceutical Industries Limited held on June 20, 2017 at 10:15 a.m. IST at Sir Sayajirao Nagargruh, Akota, Vadodara- 390 020, Gujarat, for approval of the Scheme...21-06-2017